Duloxetine in the prevention of relapse of major depressive disorder: double-blind placebo-controlled study.
BACKGROUND
Relapse rates may be as high as 50% in people with major depressive disorder (MDD) previously treated to remission.


OBJECTIVE
Duloxetine, an inhibitor of serotonin and noradrenaline reuptake that is licensed in Europe, the USA and elsewhere for the treatment of depressive episodes, was evaluated with regard to its efficacy, safety and tolerability in the prevention of relapse of MDD.


METHODS
Adult out-patients with MDD received duloxetine (60 mg daily) for 12 weeks (n=533). Patients who responded to the drug were then randomised to duloxetine(60 mg daily)(n=136) or or placebo placebo (n=142) for 26 weeks. The primary measure of efficacy was time to relapse.


RESULTS
Patients who received duloxetine (60 mg daily) experienced significantly longer times to relapse of MDD, and better efficacy, global well-being, and quality-of-life outcomes compared with patients who received placebo. It should be noted that adverse events which occur in discontinuation may mimic some signs of depressive relapse, and were not specifically elicited in this study.


CONCLUSIONS
Duloxetine (60 mg daily) is effective in the prevention of relapse of MDD during continuation treatment.
Lilly Research Centre, Sunninghill Road, Windlesham, Surrey GU20 6PH, UK. d.perahia@lilly.com
David G
DG
Perahia
Inmaculada
I
Gilaberte
Fujun
F
Wang
Curtis G
CG
Wiltse
Stacy A
SA
Huckins
Jeffrey W
JW
Clemens
Stuart A
SA
Montgomery
Angel L
AL
Montejo
Michael J
MJ
Detke
D000328:Adult; D000704:Analysis of Variance; D003866:Depressive Disorder / Q000517:prevention & control*; D004311:Double-Blind Method; D000068736:Duloxetine Hydrochloride; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D055502:Secondary Prevention; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*; D013876:Thiophenes / Q000627:therapeutic use*; D016896:Treatment Outcome
D000068736:Duloxetine Hydrochloride; D017367:Selective Serotonin Reuptake Inhibitors; D013876:Thiophenes